Hepatocellular adenoma risk factors: Difference between revisions
Jump to navigation
Jump to search
(Mahshid) |
No edit summary |
||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Hepatocellular adenoma}} | {{Hepatocellular adenoma}} | ||
{{CMG}};{{AE}} {{ | {{CMG}};{{AE}} {{ZAS}} | ||
==Overview== | ==Overview== | ||
The most | The most important risk factor in the development of haptocellular adenoma is use of oral contraceptive medications. Other risk factors include; glycogen storage diseases, familial adenomatous polyposis, klinefelters syndrome, metabolic syndrome, obesity, long term use of anabolic androgenic steroids, vascular disorders such as portal vein agenesis, budd chiari syndrome and hereditary hemorrhagic telangiectasia. | ||
==Hepatocellular adenoma risk factors== | ==Hepatocellular adenoma risk factors== | ||
* The most potent risk factor in the development of hepatocellular adenoma is use of oral contraceptive | * The most potent risk factor in the development of hepatocellular adenoma is use of oral contraceptive medications. | ||
:*[[Drospirenone and Ethinyl estradiol]] | :*[[Drospirenone and Ethinyl estradiol]] | ||
:*[[Norethindrone acetate and Ethinyl estradiol]] | :*[[Norethindrone acetate and Ethinyl estradiol]] | ||
| Line 20: | Line 21: | ||
:* Types I, III and IV [[glycogen storage disease]] | :* Types I, III and IV [[glycogen storage disease]] | ||
:* [[Familial adenomatous polyposis]] | :* [[Familial adenomatous polyposis]] | ||
==Risk factors for malignant transformation== | ==Risk factors for malignant transformation== | ||
The risk factor for malignant transformation of hepatic adenoma to hepatocellular carcinoma is:<ref name="pmid25786843">{{cite journal| author=Aamann L, Schultz N, Fallentin E, Hamilton-Dutoit S, Vogel I, Grønbæk H| title=[Hepatocellular adenoma - new classification and recommendations]. | journal=Ugeskr Laeger | year= 2015 | volume= 177 | issue= 12 | pages= | pmid=25786843 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=25786843 }} </ref> | The risk factor for malignant transformation of hepatic adenoma to hepatocellular carcinoma is:<ref name="pmid25786843">{{cite journal| author=Aamann L, Schultz N, Fallentin E, Hamilton-Dutoit S, Vogel I, Grønbæk H| title=[Hepatocellular adenoma - new classification and recommendations]. | journal=Ugeskr Laeger | year= 2015 | volume= 177 | issue= 12 | pages= | pmid=25786843 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=25786843 }} </ref> | ||
Revision as of 15:37, 31 December 2018
|
Hepatocellular adenoma Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Hepatocellular adenoma risk factors On the Web |
|
American Roentgen Ray Society Images of Hepatocellular adenoma risk factors |
|
Risk calculators and risk factors for Hepatocellular adenoma risk factors |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1];Associate Editor(s)-in-Chief: Zahir Ali Shaikh, MD[2]
Overview
The most important risk factor in the development of haptocellular adenoma is use of oral contraceptive medications. Other risk factors include; glycogen storage diseases, familial adenomatous polyposis, klinefelters syndrome, metabolic syndrome, obesity, long term use of anabolic androgenic steroids, vascular disorders such as portal vein agenesis, budd chiari syndrome and hereditary hemorrhagic telangiectasia.
Hepatocellular adenoma risk factors
- The most potent risk factor in the development of hepatocellular adenoma is use of oral contraceptive medications.
- Drospirenone and Ethinyl estradiol
- Norethindrone acetate and Ethinyl estradiol
- Norgestimate and Ethinyl estradiol
- Norgestrel and Ethinyl estradiol
- The risk is proportional to:[1]
- Hormonal dose
- Duration of medication
- Other risk factors include:[1]
- Clomiphene
- Methyl testosterone
- Danazol
- Klinefelter's syndrome
- Types I, III and IV glycogen storage disease
- Familial adenomatous polyposis
Risk factors for malignant transformation
The risk factor for malignant transformation of hepatic adenoma to hepatocellular carcinoma is:[2]
- Gender (men)
- Size (> 8 cm)
- Subtype (beta-catenin-activated HCA)
References
- ↑ 1.0 1.1 Barthelmes L, Tait IS (2005). "Liver cell adenoma and liver cell adenomatosis". HPB (Oxford). 7 (3): 186–96. doi:10.1080/13651820510028954. PMC 2023950. PMID 18333188.
- ↑ Aamann L, Schultz N, Fallentin E, Hamilton-Dutoit S, Vogel I, Grønbæk H (2015). "[Hepatocellular adenoma - new classification and recommendations]". Ugeskr Laeger. 177 (12). PMID 25786843.